Table 2.
Performance of the biomarkers for the diagnosis of cholangiocarcinoma (%) (95% CI)
| Tumor markers (cut-off value) | Sensitivity | Specificity | PPV | NPV | LR+ | LR- |
| MMP7 (5.5 ng/mL) | 75 (63-86) | 78 (71-85) | 61 (50-72) | 87 (81-93) | 3.41 (2.38-4.89) | 0.33 (0.21-0.51) |
| MMP7 (6.5 ng/mL) | 63 (50-75) | 87 (81-93) | 69 (56-81) | 83 (77-90) | 4.72 (2.91-7.66) | 0.43 (0.31-0.60) |
| MMP7 (7.5 ng/mL) | 53 (40-65) | 92 (88-97) | 76 (62-89) | 81 (74-87) | 6.73 (3.54-12.70) | 0.51 (0.39-0.68) |
| CA19-9 (35 U/mL) | 71 (60-83) | 73 (66-81) | 55 (44-66) | 85 (78-91) | 2.68 (1.93-3.73) | 0.39 (0.26-0.59) |
| CA19-9 (100 U/mL) | 68 (56-80) | 87 (81-93) | 70 (58-82) | 85 (79-91) | 5.1 (3.17-8.22) | 0.37 (0.25-0.54) |
| CA19-9 (200 U/mL) | 59 (47-72) | 93 (89-97) | 80 (68-91) | 83 (77-89) | 8.44 (4.34-16.40) | 0.44 (0.32-0.60) |
PPV: Positive predictive value; NPV: Negative predictive value; LR+: Positive likelihood ratio; LR-: Negative likelihood ratio; CI: Confidence interval; MMP7: Matrix metalloproteinase-7; CA19-9: Carbohydrate antigen 19-9.